Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Darrah E, Giles JT, Davis RL, Naik P, Wang H, Konig MF, Cappelli LC, Bingham CO 3rd, Danoff SK, Andrade F.

Front Immunol. 2018 Nov 20;9:2696. doi: 10.3389/fimmu.2018.02696. eCollection 2018.

2.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

3.

Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.

Navarro-Millán I, Darrah E, Westfall AO, Mikuls TR, Reynolds RJ, Danila MI, Curtis JR; CLEAR Investigators, Rosen A, Bridges SL Jr.

Arthritis Res Ther. 2016 Oct 22;18(1):241.

4.

High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.

Blachère NE, Parveen S, Frank MO, Dill BD, Molina H, Orange DE.

Arthritis Rheumatol. 2017 May;69(5):986-995. doi: 10.1002/art.40035.

5.

Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.

Damgaard D, Bawadekar M, Senolt L, Stensballe A, Shelef MA, Nielsen CH.

PLoS One. 2018 Aug 30;13(8):e0203214. doi: 10.1371/journal.pone.0203214. eCollection 2018.

6.

Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.

Seaman A, Darrah E, Infantino M, Meacci F, Manfredi M, Benucci M, Mahler M.

Autoimmun Rev. 2016 Jul;15(7):776-80. doi: 10.1016/j.autrev.2016.03.016. Epub 2016 Mar 18. Review.

PMID:
26997641
7.

Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.

Ferucci ED, Darrah E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM, Fritzler MJ, Rosen A, El-Gabalawy HS.

J Rheumatol. 2013 Sep;40(9):1523-8. doi: 10.3899/jrheum.130293. Epub 2013 Aug 1.

8.

Increased levels of peptidylarginine deiminase 2 in synovial fluid from anti-CCP-positive rheumatoid arthritis patients: Association with disease activity and inflammatory markers.

Damgaard D, Senolt L, Nielsen CH.

Rheumatology (Oxford). 2016 May;55(5):918-27. doi: 10.1093/rheumatology/kev440. Epub 2016 Feb 15.

9.

Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.

Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, Bathon JM.

PLoS One. 2014 Jun 5;9(6):e98794. doi: 10.1371/journal.pone.0098794. eCollection 2014.

10.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

11.

Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.

Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, Ocampo-Bermudes G, Muñoz-Valle JF.

Clin Exp Immunol. 2015 Nov;182(2):119-31. doi: 10.1111/cei.12677. Epub 2015 Sep 16.

12.

Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.

Darrah E, Rosen A, Giles JT, Andrade F.

Ann Rheum Dis. 2012 Jan;71(1):92-8. doi: 10.1136/ard.2011.151712. Epub 2011 Aug 21.

13.

Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.

Schwenzer A, Jiang X, Mikuls TR, Payne JB, Sayles HR, Quirke AM, Kessler BM, Fischer R, Venables PJ, Lundberg K, Midwood KS.

Ann Rheum Dis. 2016 Oct;75(10):1876-83. doi: 10.1136/annrheumdis-2015-208495. Epub 2015 Dec 9.

14.

Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.

Umeda N, Matsumoto I, Kawaguchi H, Kurashima Y, Kondo Y, Tsuboi H, Ogishima H, Suzuki T, Kagami Y, Sakyu T, Ishigami A, Maruyama N, Sumida T.

Clin Rheumatol. 2016 May;35(5):1181-8. doi: 10.1007/s10067-015-3082-z. Epub 2015 Sep 29.

PMID:
26415740
15.

Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.

Reyes-Castillo Z, Muñoz-Valle JF, Llamas-Covarrubias MA.

Autoimmun Rev. 2018 Feb;17(2):94-102. doi: 10.1016/j.autrev.2017.11.023. Epub 2017 Dec 2. Review.

PMID:
29196243
16.

Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.

Bawadekar M, Shim D, Johnson CJ, Warner TF, Rebernick R, Damgaard D, Nielsen CH, Pruijn GJM, Nett JE, Shelef MA.

J Autoimmun. 2017 Jun;80:39-47. doi: 10.1016/j.jaut.2017.01.006. Epub 2017 Feb 7.

17.

Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning.

Badillo-Soto MA, Rodríguez-Rodríguez M, Pérez-Pérez ME, Daza-Benitez L, Bollain-Y-Goytia JJ, Carrillo-Jiménez MA, Avalos-Díaz E, Herrera-Esparza R.

Eur J Rheumatol. 2016 Jun;3(2):44-49. Epub 2016 Feb 1.

18.

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.

Schwedler C, Häupl T, Kalus U, Blanchard V, Burmester GR, Poddubnyy D, Hoppe B.

Arthritis Res Ther. 2018 Mar 14;20(1):44. doi: 10.1186/s13075-018-1540-0.

19.

Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.

Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø.

Ann Rheum Dis. 2008 Mar;67(3):414-7. Epub 2007 Nov 15.

PMID:
18006540
20.

Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.

Shimada A, Kobayashi T, Ito S, Okada M, Murasawa A, Nakazono K, Yoshie H.

J Periodontal Res. 2016 Feb;51(1):103-11. doi: 10.1111/jre.12288. Epub 2015 Jun 11.

PMID:
26094771

Supplemental Content

Support Center